CR is definitely on the card.
- burn rate of approx AUD 5 mil per half year
- ending Dec 2023 vash available AUD 3 mil + R&D grant of 1.5M
- CR should ann within this month
- projections to cash flow positive ann last year was 80k patients based upon upfront sales and recurring monthly data fees of device. COPD patients in US stand around 16+ millions 2023 and growing. no need to rush to load up now imho due to lack of execution from the management. will wait to see the quarterly new patients onboarding figure. DYOR
Ann: US FDA clearance of Hailie for AstraZeneca inhalers, page-46
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.102M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 435003 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 224800 | 1 |
View Market Depth
| Last trade - 16.12pm 27/09/2024 (20 minute delay) ? |
| ADR (ASX) Chart |
Day chart unavailable